



ADD\_Pivotal study #1 Protocol #5







ADD\_RPS Bipolar Revised 9-8-11







ADD\_SNX PhIII AIPC







ADD\_SOC trial







ADD\_SPD476 Scenario 2 - France only







ADD\_SPD476 Scenario 2 - India only







ADD\_SPD489 Phase 3 Pivotal (Japan)







ADD\_SPD489-346 - BED FDA Add 4 wk Dose Maint (8 wk total)





ADD\_SPD551-303





ADD\_SPD557-113 crude

